SYRE Spyre Therapeutics, Inc.
Nasdaq · SEC CIK 1636282 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $436.71M 29 sales by 7 insiders
- Filings on record
- 115 since 2021-07-08, latest 2026-09-03 21:34
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Fairmount Funds Management LLC | Dir | — | $399.66M |
| Turtle Cameron | CEO, Dir | — | $9.99M |
| HENDERSON MICHAEL THOMAS | Dir | — | $7.95M |
| Sloan Sheldon | Chief Medical Off | — | $7.35M |
| Burrows Scott L | CFO | — | $6.86M |
| King-Jones Heidy | See Remarks | — | $2.48M |
| Albers Jeffrey W. | Dir | — | $2.40M |
Transactions 66
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-03 21:34 | 2026-09-01+ | SYRE | King-Jones Heidy | See Remarks | M - OptEx | $14.50 | +28.4K | 3,245 | New | +$411.8K |
| DMT | 2026-09-03 21:34 | 2026-09-01+ | SYRE | King-Jones Heidy | See Remarks | S - Sale+OE | $87.35 | -28.4K | 2,845 | -91% | -$2.48M |
| DT | 2026-09-03 21:33 | 2026-09-01 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-09-03 21:33 | 2026-09-01+ | SYRE | Burrows Scott L | CFO | S - Sale+OE | $88.75 | -25.7K | 79.8K | -24% | -$2.28M |
| MT | 2026-09-03 21:33 | 2026-09-01 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $87.29 | -15.0K | 552.5K | -3% | -$1.31M |
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | M - OptEx | $10.39 | +5,000 | 5,000 | New | +$52.0K |
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | S - Sale+OE | $104.47 | -5,000 | 0 | -100% | -$522.4K |
| DMTI | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | S - Sale+OE | $104.55 | -18.0K | 9,360 | -66% | -$1.88M |
| DT | 2026-08-05 21:32 | 2026-08-03 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-08-05 21:32 | 2026-08-03 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $95.57 | -7,500 | 98.0K | -7% | -$716.8K |
| MT | 2026-08-05 21:31 | 2026-08-03 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $95.51 | -15.0K | 567.5K | -3% | -$1.43M |
| DT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $87.74 | -7,500 | 98.0K | -7% | -$658.0K |
| DT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +8,334 | 8,334 | New | +$228.9K |
| DMT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $87.70 | -8,334 | 0 | -100% | -$730.9K |
| MT | 2026-07-02 21:32 | 2026-07-01 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $87.69 | -15.0K | 582.5K | -3% | -$1.32M |
| D | 2026-06-26 21:31 | 2026-06-25 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +15.0K | 113.0K | +15% | +$217.5K |
| DM | 2026-06-26 21:31 | 2026-06-25 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $87.13 | -15.0K | 98.0K | -13% | -$1.31M |
| DI | 2026-06-23 21:56 | 2026-06-23 | SYRE | Fairmount Funds Management LLC | Dir | C - Cnv Deriv | — | +666.7K | 4.68M | +17% | — |
| DI | 2026-06-23 21:56 | 2026-06-23 | SYRE | Fairmount Funds Management LLC | Dir | S - Sale | $85.31 | -4.68M | 0 | -100% | -$399.66M |
| T | 2026-06-23 21:32 | 2026-06-22 | SYRE | HENDERSON MICHAEL THOMAS | Dir | S - Sale | $100.00 | -20.0K | 68.6K | -23% | -$2.00M |
| DT | 2026-06-03 21:32 | 2026-06-03 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +8,333 | 8,333 | New | +$228.8K |
| DT | 2026-06-03 21:32 | 2026-06-03 | SYRE | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $75.00 | -8,333 | 0 | -100% | -$625.0K |
| MT | 2026-06-03 21:31 | 2026-06-01 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $70.43 | -15.0K | 597.5K | -2% | -$1.06M |
| DT | 2026-06-03 21:30 | 2026-06-01 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-06-03 21:30 | 2026-06-01 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $71.06 | -7,500 | 98.0K | -7% | -$532.9K |
| MT | 2026-05-08 21:31 | 2026-05-08 | SYRE | HENDERSON MICHAEL THOMAS | Dir | S - Sale | $74.40 | -80.0K | 88.6K | -47% | -$5.95M |
| DT | 2026-05-01 21:35 | 2026-05-01 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +12.5K | 110.5K | +13% | +$181.2K |
| DT | 2026-05-01 21:35 | 2026-05-01 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $71.37 | -12.5K | 98.0K | -11% | -$892.1K |
| DT | 2026-05-01 21:34 | 2026-05-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +78.3K | 78.3K | New | +$2.15M |
| DMT | 2026-05-01 21:34 | 2026-05-01 | SYRE | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $71.50 | -78.3K | 0 | -100% | -$5.60M |
| MT | 2026-05-01 21:34 | 2026-05-01 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $71.37 | -15.0K | 612.5K | -2% | -$1.07M |
| MT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $49.33 | -15.0K | 627.5K | -2% | -$739.9K |
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $21.66 | +7,958 | 7,958 | New | +$172.4K |
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $50.00 | -7,958 | 0 | -100% | -$397.9K |
| DT | 2026-04-03 21:29 | 2026-04-01 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-04-03 21:29 | 2026-04-01 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $49.34 | -7,500 | 98.0K | -7% | -$370.1K |
| M | 2026-03-03 | 2026-03-02 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $42.19 | -15.0K | 651.6K | -2% | -$632.9K |
| DM | 2026-03-03 | 2026-03-03 | SYRE | Burrows Scott L | CFO | S - Sale+OE | $40.65 | -2,500 | 98.2K | -2% | -$101.6K |
| D | 2026-03-03 | 2026-03-03 | SYRE | Burrows Scott L | CFO | M - OptEx | $14.50 | +2,500 | 100.5K | +3% | +$36.2K |
| M | 2026-02-04 | 2026-02-02 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $32.80 | -15.0K | 657.5K | -2% | -$492.0K |
| 2026-01-23 | 2026-01-21 | SYRE | HENDERSON MICHAEL THOMAS | Dir | J - Other | $0.00 | +63.2K | 168.6K | +60% | $0 | |
| M | 2026-01-06 | 2026-01-02 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $30.68 | -15.0K | 672.0K | -2% | -$460.1K |
| M | 2025-12-03 | 2025-12-01 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $29.02 | -15.0K | 690.9K | -2% | -$435.4K |
| M | 2025-11-05 | 2025-11-03 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $23.33 | -45.0K | 701.9K | -6% | -$1.05M |
| 2025-09-03 | 2025-09-02 | SYRE | Burrows Scott L | CFO | S - Sale | $16.26 | -18.4K | 98.0K | -16% | -$299.6K | |
| 2025-01-14 | 2025-01-10 | SYRE | HENDERSON MICHAEL THOMAS | Dir | J - Other | $0.00 | +105.4K | 105.4K | New | $0 | |
| I | 2024-11-08 | 2024-11-06 | SYRE | Albers Jeffrey W. | Dir | S - Sale | $36.76 | -6,700 | 27.4K | -20% | -$246.3K |
| I | 2024-10-28 | 2024-10-25 | SYRE | Albers Jeffrey W. | Dir | S - Sale | $36.43 | -300 | 34.1K | -0.9% | -$10.9K |
| 2024-09-05 | 2024-09-03 | SYRE | Burrows Scott L | CFO | S - Sale | $28.17 | -18.5K | 116.4K | -14% | -$522.0K | |
| DI | 2024-04-25 | 2024-04-25 | SYRE | Harwin Peter Evan | Dir | M - OptEx | $0.00 | +3.64M | 4.02M | +962% | $0 |
| 2024-02-20 | 2024-02-15 | SYRE | Turtle Cameron | CEO, Dir | A - Grant | $9.82 | +400 | 746.9K | +0.1% | +$3,928 | |
| MTI | 2023-12-29 | 2023-12-29 | SYRE | Fairmount Healthcare Fund II L.P. | Dir, 10% | J - Other | $0.00 | -2.62M | 0 | -100% | $0 |
| 2023-12-22 | 2023-12-22 | SYRE | Burrows Scott L | CFO | A - Grant | $0.00 | +135.0K | 135.0K | New | $0 | |
| DAI | 2023-12-08 | 2023-11-24 | SYRE | Albers Jeffrey W. | Dir | C - Cnv Deriv | $0.00 | +34.4K | 34.4K | New | $0 |
| DI | 2023-11-28 | 2023-11-24 | SYRE | Fairmount Healthcare Co-Invest L.P. | Dir, 10% | C - Cnv Deriv | $0.00 | +3.44M | 3.44M | New | $0 |
| D | 2023-11-27 | 2023-11-24 | SYRE | Turtle Cameron | CEO, Dir | C - Cnv Deriv | $0.00 | +723.4K | 746.5K | +3,136% | $0 |
| 2022-08-25 | 2022-08-25 | SYRE | Souza Marcio | Dir | P - Purchase | $0.56 | +90.0K | 90.0K | New | +$50.4K | |
| 2022-06-10 | 2022-06-08 | SYRE | Hanley Jr. Michael Conick | Chief Commercial Off | P - Purchase | $0.71 | +28.2K | 36.2K | +352% | +$20.0K | |
| 2022-03-18 | 2022-03-16 | SYRE | Quinn Anthony G. | Pres, CEO, Dir | P - Purchase | $2.34 | +80.1K | 550.5K | +17% | +$187.4K | |
| M | 2022-03-15 | 2022-03-11+ | SYRE | Quinn Anthony G. | Pres, CEO, Dir | P - Purchase | $1.94 | +144.7K | 473.5K | +44% | +$280.8K |
| 2022-03-15 | 2022-03-11 | SYRE | Alspaugh Jonathan | CFO | P - Purchase | $2.08 | +75.0K | 165.4K | +83% | +$156.0K | |
| 2021-12-13 | 2021-12-09 | SYRE | Alspaugh Jonathan | CFO | P - Purchase | $3.72 | +50.0K | 90.4K | +124% | +$186.0K | |
| M | 2021-12-13 | 2021-12-09+ | SYRE | Quinn Anthony G. | Pres, CEO, Dir | P - Purchase | $3.71 | +53.6K | 318.3K | +20% | +$199.0K |
| M | 2021-12-13 | 2021-12-09+ | SYRE | Shanafelt Armen | Dir | P - Purchase | $3.67 | +150.0K | 150.0K | New | +$549.9K |
| M | 2021-08-18 | 2021-08-16+ | SYRE | Alspaugh Jonathan | CFO | P - Purchase | $6.51 | +40.4K | 9,780 | New | +$262.7K |
Purchase Sale Sale after option exercise All abbreviations